PerkinElmer to Acquire UK In-Vitro Diagnostics Company Immunodiagnostic Systems

PerkinElmer, Inc. (Waltham, MA; USA) and Immunodiagnostic Systems Holdings PLC (IDS; Boldon, Tyne and Wear, UK) have reached an agreement whereby PerkinElmer will acquire IDS for approximately USD 155 million.

IDS develops, manufactures, and markets innovative immunoassays and automated immunoanalyzer technologies to provide improved diagnostic outcomes for patients. IDS’s immunoassay portfolio is a combination of an endocrinology specialty testing menu and assay panels in complementary fields. PerkinElmer's comprehensive global diagnostics portfolio includes solutions focused on: reproductive health; autoimmune, infectious disease and allergy testing; gene analyses; and genomics offerings for oncology and other molecular tests through its wide range of instruments, reagents, assay platforms and software offerings.


Through this acquisition, PerkinElmer will be able to grow its overall Diagnostics business and specifically its immunodiagnostics segment. Moreover, the deal will enable PerkinElmer to combine its channel expertise and testing capabilities with IDS’ best-in-class chemiluminescence products in endocrinology, autoimmunity and infectious diseases to better serve customers around the world. IDS’s portfolio and expertise will seamlessly integrate within EUROIMMUN, a PerkinElmer company since 2017. EUROIMMUN is a global leader in autoimmune testing and an emerging force in infectious disease, allergy and molecular genetic testing.

“This proposed transaction is highly valuable for both parties as the respective product lines are to a large extent complementary,” said Wolfgang Schlumberger, CEO of EUROIMMUN. “The cooperation of our global distribution channels, the expansion of the immunoassay portfolio in closely related indication fields and IDS's fully automated random access chemiluminescence platform strengthens our presence in immunodiagnostics. Our customers will benefit from a broader range of assays and laboratory diagnostic workflows. We are excited about these new opportunities and we look forward to welcoming Immunodiagnostic Systems into the PerkinElmer family following the completion of the transaction.”

Related Links:
PerkinElmer, Inc.
Immunodiagnostic Systems Holdings PLC (IDS)